Pradaxa - (75,150 mg; Capsule, Oral)

Generic Name	Dabigatran Etexilate Mesylate	**Innovator**	Boehringer Ingelheim
Dosage	75,150 mg; Capsule, Oral	**Branded US Sales**	Less Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	More Than 5
Other ANDA developers	More Than 5	**Tentative Approvals**	Less Than 5
Final Approvals	More Than 5	**Generic Launches**	More Than 5
Indication	Indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Pradaxa - (110mg; Capsule, Oral)

Generic Name	Dabigatran Etexilate Mesylate	**Innovator**	Boehringer Ingelheim
Dosage	110mg; Capsule, Oral	**Branded US Sales**	Less Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	More Than 5
Other ANDA developers	More Than 5	**Tentative Approvals**	Less Than 5
Final Approvals	More Than 5	**Generic Launches**	More Than 5
Indication	Indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.